FUNDAMENTALS · Fundamentals · HK Healthcare

HUTCHMED (China) (0013) Fundamentals 2026 — P/E 4.2x, Revenue Analysis | SniperIQ

HUTCHMED (China) (0013) is a HK-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of HK

5.3B, trading at HK
7.83 on the HKSE. This SniperIQ fundamentals page covers HUTCHMED (China)'s valuation (P/E 4.2x, P/B 18.5x), profitability (net margin 83.3%), revenue ($549M in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.

Market CapHK
5.3B
P/E (TTM)4.2x
Net Margin83.3%
Revenue (FY25)$549M

Full research coverage

  • 8-Quarter Revenue & Margin Trend
  • Debt Maturity & Coverage
  • Peer Valuation Comparison
  • Free Cash Flow & Owner Earnings
  • AI Signal + Institutional Flow
  • DCF Valuation Model

Frequently Asked Questions

What is HUTCHMED (China)'s market cap?

HUTCHMED (China) (0013) has a market capitalization of approximately HK

5.3B, trading at HK
7.83 on the HKSE. Market cap moves with the live share price.

What is HUTCHMED (China)'s P/E ratio?

HUTCHMED (China)'s trailing twelve-month P/E ratio is 4.2x, with a price-to-book (P/B) of 18.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.

How profitable is HUTCHMED (China)?

HUTCHMED (China) runs a net profit margin of 83.3%, a gross margin of 11.6%, and an operating margin of -7.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.

How much revenue does HUTCHMED (China) generate?

HUTCHMED (China) reported revenue of $549M for fiscal year 2025, with net income of $457M and earnings per share (EPS) of 0.53. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.

Does HUTCHMED (China) pay a dividend?

HUTCHMED (China) does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.

Is HUTCHMED (China) financially healthy?

HUTCHMED (China) carries a debt-to-equity ratio of 0.08x and a current ratio of 4.96x, with a market beta of 0.43. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.

Is HUTCHMED (China) a good stock to buy in 2026?

SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For HUTCHMED (China) (0013) the key facts are: market cap HK

5.3B, P/E 4.2x, revenue $549M, 52-week range 15.57-30.75. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.

Track HUTCHMED (China)'s full fundamentals live

Get HUTCHMED (China)'s 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.

Related: Tonghua Golden-Horse Pharmaceutical Industry (000766) fundamentals · Amrutanjan Health Care (AMRUTANJAN) fundamentals · Xcell Therapeutics (373110) fundamentals · Medpace Holdings (MEDP) fundamentals · All stock fundamentals · AI signal library
Research Hubs: Fundamentals library · Screeners · Institutional positioning · Super investors · Daily signals · Platform comparisons